The Food and Drug Administration (FDA) has approved Isturisa® (osilodrostat; Recordati) for the treatment of adults with Cushing disease for whom pituitary surgery is not an option or has not been curative.
No reference criteria can definitively distinguish patients with primary aldosteronism and subclinical Cushing syndrome from those with these conditions alone.
According to results of the phase 3 SONICS trial, levoketoconazole is a safe and effective treatment option for patients with Cushing syndrome.
Researchers examined sex differences in clinical presentation and patient outcomes in ACTH-dependent Cushing syndrome.
Patients with AMH without pheochromocytoma had milder symptoms compared with patients with pheochromocytoma only.
Mifepristone may be an effective alternative to adrenalectomy in patients with hypercortisolism caused by primary bilateral macronodular adrenal hyperplasia.
In the absence of clear evidence of a pituitary adenoma on imaging, there is some controversy regarding the best treatment for Cushing disease.
Prevalence of diabetes is higher in patients with primary aldosteronism and was found to be related to suspected subclinical hypercortisolism.
Researchers reported that mean urinary-free cortisol (mUFC) normalization with Recorlev was similar in patients with and without diabetes.
Plasma levels of the orexigenic neuropeptide agouti-related protein (AgRP) are elevated in Cushing disease, and it may be a marker of hypothalamic AgRP.
Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).